山东威高血液净化制品股份有限公司2025年度“提质增效重回报”行动方案

Core Viewpoint - The company has developed a "2025 Quality Improvement and Efficiency Enhancement Action Plan" aimed at optimizing operational efficiency, improving corporate governance, and enhancing investor returns, thereby driving high-quality development and increasing investment value [1][10]. Group 1: Business Focus and Market Strategy - The company focuses on the research, production, and sales of blood purification medical products, including hemodialyzers, dialysis tubing, dialysis machines, and peritoneal dialysis solutions, making it one of the most comprehensive manufacturers in the domestic market [1][2]. - The company aims to become a "global leader in comprehensive blood purification solutions," with sales covering over 6,000 medical institutions across all provinces and regions in China [1]. - The company is expanding its global market presence, particularly in Southeast Asia, South America, Eastern Europe, and North Africa, leveraging local production advantages to meet new customer demands [2]. Group 2: Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, and specialized committees, ensuring clear division of responsibilities and effective coordination [3]. - In response to regulatory changes, the company has revised several internal regulations to strengthen its governance framework and enhance sustainable development [3]. Group 3: Information Disclosure and Investor Relations - The company emphasizes high-quality information disclosure, adhering to relevant laws and regulations to ensure timely and accurate communication of its operational dynamics and value to the market [4]. - The company has established diverse communication channels to engage with investors, ensuring that their rights to information and participation are protected [4]. Group 4: Investor Returns - The company prioritizes reasonable returns for investors, implementing a cash dividend policy that aligns with long-term development and shareholder interests [5]. - For the mid-2025 dividend, the company plans to distribute 1.6 yuan (including tax) per 10 shares, totaling 65.82 million yuan, which accounts for 29.89% of the net profit for the period [5]. Group 5: Management of Key Personnel - The company maintains close communication with key stakeholders, including controlling shareholders and senior management, to enhance compliance awareness and responsibility [6]. - The company will continue to monitor regulatory changes and provide training to key personnel to ensure adherence to compliance standards and promote sustainable development [6].